Novo Nordisk to Invest $80 million into the Expansion of its Denmark Production Site

Currently, the facility manufactures products for oral diabetes treatment and will be expanded to increase capacity for these products.

Novo Nordisk announced on Feb. 25, 2021 that it is investing DKK 500 million (US$80 million) into the expansion of its facilities at its production site in Måløv, Denmark.

Currently, the facility manufactures products for oral diabetes treatment and will be expanded to increase capacity for these products, Novo Nordisk said in a company press release. The expansion is set to be completed in 2022.

“This investment in our production facilities in Måløv is an important step in building and ensuring future capacity for production of Rybelsus (oral semaglutide). Måløv is currently our cornerstone in the production of oral semaglutide, and it is critical that we invest timely in capacity expansion to meet the future demands,” said Henrik Steen Jensen, corporate vice-president for Novo Nordisk oral semaglutide production, in the press release.

Source: Novo Nordisk